Kidney transplantation at extremes of age: CsA eliminates the increased risk in recipients < or = 5 or > or = 55 years.
MacDonell
R C
RC
Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-2584.
Van Buren
D H
DH
Richie
R E
RE
Johnson
H K
HK
Nylander
W A
WA
Helderman
J H
JH
Ynares
C M
CM
Trusler
L A
LA
Green
W F
WF
Crowe
D A
DA
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007223:Infant; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone